Retina DiseaseNCT07143851
Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases
An observational study of Retina Disease and Glaucoma, run by Beijing Hospital.
Trial summary
Aiming at the problems of low image reading efficiency, crowded medical resources and fragmented cross-modal information of ophthalmic OCT and OCTA, a multimodal large model diagnostic framework for various diseases such as retinal diseases and optic nerve damage in glaucoma is constructed to fully explore the… Read more about this study
- Who is it for?
- Ages 20 to 90 years
- Conditions the study is for
- Retina Disease, Glaucoma
- What is being tested?
- Not applicable- observational study
- How many people
- 5,000 participants
- Where
- No sites listed yet
- Study dates
- 30 Aug 2025to 30 Jun 2028
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed as macular degeneration, diabetic macular edema, retinal vein obstructive macular edema, high myopia, glaucoma or other clearly diagnosed ophthalmic diseases.
Who may be able to join
- Diagnosed as macular degeneration, diabetic macular edema, retinal vein obstructive macular edema, high myopia, glaucoma or other clearly diagnosed ophthalmic diseases. The SS-OCT/SS-OCTA images of the patient are clear.
Who cannot join
- The image quality is poor and difficult to analyze due to reasons such as refractive media opacity and poor coordination.
About this study
Official title: Research on Key Technologies of Intelligent Auxiliary Diagnosis for Multiple Eye Diseases Based on Multimodal Ultra-High-Speed SS-OCT/OCTA
Aiming at the problems of low image reading efficiency, crowded medical resources and fragmented cross-modal information of ophthalmic OCT and OCTA, a multimodal large model diagnostic framework for various diseases such as retinal diseases and optic nerve damage in glaucoma is constructed to fully explore the complementary information of various images such as SS-OCT structural images, SS-OCTA vascular images and optic nerve scans. Extract cross-modal joint features to improve the accuracy of automatic diagnosis.
- Conditions
- Retina Disease, Glaucoma
- Being tested
- Not applicable- observational study
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Not applicable- observational studyOther
There is no special intervention method
What is being measured
The primary outcome is the main question the study is designed to answer.
CMT
Central macular thickness measured on OCT
Measured: Baseline
Secondary outcomes (1)
SS-OCT/OCTA images
Multimodal features based on patients' iamges
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2025
- Study start30 Aug 2025 (estimated)
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retina DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 5,000 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Beijing Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07143851
- Sponsor's protocol ID
- BJ-2025-092
- Status last verified
- Aug 2025
- First submitted
- 29 Jul 2025
- Last updated
- 27 Aug 2025
- Results posted
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Research on Key Technologies of Intelligent Auxiliary Diagnosis for Multiple Eye Diseases Based on Multimodal Ultra-High-Speed SS-OCT/OCTA
- ClinicalTrials.gov ID
- NCT07143851
- Acronym / sponsor ID
- BJ-2025-092
- Conditions
- Retina Disease, Glaucoma
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Beijing HospitalOther government
- Study start
- 30 Aug 2025 (estimated)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 27 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aiming at the problems of low image reading efficiency, crowded medical resources and fragmented cross-modal information of ophthalmic OCT and OCTA, a multimodal large model diagnostic framework for various diseases such as retinal diseases and optic nerve damage in glaucoma is constructed to fully explore the complementary information of various images such as SS-OCT structural images, SS-OCTA vascular images and optic nerve scans. Extract cross-modal joint features to improve the accuracy of automatic diagnosis.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 20 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed as macular degeneration, diabetic macular edema, retinal vein obstructive macular edema, high myopia, glaucoma or other clearly diagnosed ophthalmic diseases.
Key inclusion criteria (1 listed)
- Diagnosed as macular degeneration, diabetic macular edema, retinal vein obstructive macular edema, high myopia, glaucoma or other clearly diagnosed ophthalmic diseases. The SS-OCT/SS-OCTA images of the patient are clear.
Key exclusion criteria (1 listed)
- The image quality is poor and difficult to analyze due to reasons such as refractive media opacity and poor coordination.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Not applicable- observational studyThere is no special intervention method | Other | – |
Primary outcome
CMT
Time frame: Baseline
Central macular thickness measured on OCT
1 secondary outcome
SS-OCT/OCTA images
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Retina Disease
Active, not recruitingPhase 4
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
Geographic Atrophy, Age-Related Macular Degeneration
RecruitingPhase 2
A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)
Participants With Underactive Bladder (UAB)
RecruitingObservational study
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
Age-Related Macular Degeneration
Active, not recruitingPhase 1/2
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
Geographic Atrophy
RecruitingPhase 3
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
Diabetic Macular Edema (DME)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Retina Disease and Glaucoma, run by Beijing Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CMT (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2025.